About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.490 +0.010 (+0.68%)
Streaming Delayed Price Updated: 12:59 PM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
INmune Bio Inc. to Join Russell 3000® Index
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024 ↗
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
A Preview Of INmune Bio's Earnings ↗
 
Via Benzinga
News headline image
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023 ↗
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 28, 2024 ↗
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
News headline image
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Why Is Elevai Labs (ELAB) Stock Up Today? ↗
Elevai Labs is soaring on an intriguing licensing agreement with INmune Bio, but the narrative presents a mixed bag for ELAB stock. 
Via InvestorPlace
News headline image
Why Elevai Labs Stock Is Trading Higher ↗
Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune... 
Via Benzinga
News headline image
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost 
From Elevai Labs Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! 
Via InvestorPlace
News headline image
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
News headline image
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open... 
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.